Drug Profile
Research programme: schizophrenia and Alzheimer's disease therapeutics - Orion Pharma
Alternative Names: ORM-14540Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Orion
- Class
- Mechanism of Action Alpha 2c adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Schizophrenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Alzheimer's-disease in Finland
- 04 Nov 2017 No recent reports of development identified for research development in Schizophrenia in Finland (IV)
- 02 Aug 2011 Early research in Alzheimer's disease in Finland (unspecified route)